Critic of Covid boosters set to enact tough agenda as top US vaccines official

TruthLens AI Suggested Headline:

"Vinay Prasad Appointed as Top Official at US FDA's Vaccine Division Amid Controversial Stance on Covid Vaccines"

View Raw Article Source (External Link)
Raw Article Publish Date:
AI Analysis Average Score: 5.2
These scores (0-10 scale) are generated by Truthlens AI's analysis, assessing the article's objectivity, accuracy, and transparency. Higher scores indicate better alignment with journalistic standards. Hover over chart points for metric details.

TruthLens AI Summary

Vinay Prasad, an oncologist and hematologist known for his critical stance on pharmaceutical regulations, has been appointed as the top official of the Center for Biologics Evaluation and Research (CBER) within the US Food and Drug Administration (FDA). His appointment has raised concerns, particularly among biotech investors, as Prasad has long advocated for stricter regulatory scrutiny of new medications and has made controversial statements regarding Covid vaccines. He has called for extensive studies on the safety of childhood vaccines, despite previous research debunking such claims. In recent years, Prasad has gained notoriety for his opposition to Covid boosters and other pandemic precautions, suggesting that the risks associated with vaccines may outweigh their benefits. His views have been met with criticism from public health experts who argue that he has spread misinformation about Covid-19 and the vaccine's efficacy, particularly regarding the safety of mRNA vaccines in children.

Prasad's leadership role at CBER will involve overseeing more than 1,000 employees, although he lacks extensive leadership experience beyond his research lab. His tenure is likely to shift the regulatory landscape, as he has proposed making randomized trials less bureaucratic and more cost-effective. He has also been vocal about reforming the approval processes for vaccines, including calling for clinical trials to assess the effectiveness of updated Covid shots based on age groups. This approach, while unconventional, could delay the availability of vaccines and complicate the flu vaccine process as well. Critics have pointed out that Prasad's aggressive criticisms of the public health establishment and his use of inflammatory language may undermine confidence in regulatory decisions. His recent appointment signals a potential shift in how the FDA approaches vaccine approval and public health policy, raising questions about the implications for ongoing vaccination efforts as the virus continues to evolve.

TruthLens AI Analysis

The article presents an intriguing look at the recent appointment of Vinay Prasad as the top US vaccines official. His known skepticism towards Covid boosters and the pharmaceutical industry raises questions about the future direction of vaccine regulation in the United States. The implications of his leadership could have far-reaching effects on public health policies and the pharmaceutical market.

Public Sentiment and Perception

By highlighting Prasad's criticisms of Covid vaccines and his lack of traditional leadership experience, the article seems to aim at generating skepticism and concern among the public regarding vaccine safety and regulatory practices. This could foster a narrative that questions the efficacy and necessity of Covid boosters, potentially influencing public sentiment against vaccination efforts, especially in light of ongoing vaccination campaigns.

Potential Information Gaps

The article does not address the broader context of Prasad's statements and the scientific consensus on vaccine safety and efficacy, particularly regarding childhood vaccinations and autism. This omission might lead the public to misunderstand the scientific backing behind vaccination protocols, suggesting a manipulation of information to support a particular narrative.

Manipulative Aspects of the Reporting

The article could be seen as manipulative, particularly in its focus on Prasad's criticisms without providing counterarguments or the consensus of the medical community. The language used may evoke fear and uncertainty about vaccines, which might not represent the majority opinion in the scientific community. This selective presentation of information could be aimed at shaping public opinion against the current vaccination strategies.

Overall Trustworthiness

While the article presents factual information regarding Prasad's background and appointment, the selective emphasis on his criticisms and the lack of context regarding the scientific consensus makes it less trustworthy. The potential for bias in how the information is presented suggests that readers should approach the article with caution, considering the broader context of vaccine science and public health recommendations.

Impact on Markets and Public Health

The announcement of Prasad's appointment has already led to a decline in biotech stocks, indicating that investors are concerned about tighter regulations that could affect the pharmaceutical industry. The apprehension surrounding his leadership may result in decreased investment in vaccine development, which can have long-term consequences for public health initiatives.

Target Audience

The article seems designed to resonate with individuals skeptical of vaccines and those critical of the pharmaceutical industry. By framing Prasad's appointment within the context of regulatory scrutiny, it appeals to those who prioritize cautious approaches to medical interventions.

In summary, the article casts Vinay Prasad's appointment in a light that raises doubts about vaccine safety and regulatory practices. The selective nature of the information presented potentially manipulates public perception, urging readers to question established vaccine protocols while not fully addressing the scientific consensus on the matter.

Unanalyzed Article Content

Vinay Prasad, an oncologist and hematologist who has called for more regulatory scrutiny of pharmaceuticals, including Covid vaccines, was named the top US vaccines official earlier this month.

Marty Makary, commissioner of the US Food and Drug Administration (FDA), announced in a 6 May email obtained by the Guardian that Prasad would now lead the Center for Biologics Evaluation and Research (CBER), which oversees biological products like blood, vaccines, and cellular and gene therapies. Biotech stocksplungedat the news.

Prasad has signaled, in blogposts, podcast episodes and social media posts, that he is likely to enact tougher regulatory scrutiny for new therapies, especially when it comes to the rapid approval of new medications.

He has also repeatedly decried Covid boosters and called for extensive studies to see whether grouping childhood vaccines together causes autism, which multiple studies have debunked.

Since 2020, Prasad has been a professor of epidemiology and biostatistics and medicine at the University of California, San Francisco, and he sees patients at San Francisco general hospital.

He islicensedas a physician, but he isno longerboard-certified in internal medicine, hematology, or oncology – which means he’s unlikely to continue practicing clinical medicine, said David Gorski, a professor of surgery and oncology at Wayne State University.

“There are a lot of doctors who, when they transition to a non-clinical position, let their board certifications lapse because it’s expensive and a lot of work to keep them up – but it’s unusual for someone that young,” Gorski said.

Prasad will oversee more than 1,000 employees at the CBER, but does not seem to have held previous leadership positions beyond his research lab. He did not respond to the Guardian’s interview request.

An analysis of Prasad’s public statements reveals an outspoken critic of the pharmaceutical industry – and of his peers in public health.

Prasad hascalled outthe practice of pharmaceutical companies offering payments to doctors. He has strongly advocated for limitations on the relationships between pharmaceutical companies and regulators,arguingthat regulators with recent pharma work, such as running clinical trials, should be removed, andrecommendingthat regulators should not have consulted for pharma for five years before joining the FDA.

Prasad has alsoproposedmaking randomized trials less bureaucratic and thus less expensive. He has long pushed for stronger regulations around the approval of new medications, especially for cancer and forrare conditionssuch as Duchenne muscular dystrophy.

In the accelerated approval process, regulators “didn’t follow up on these trials to make sure that the post-marketing licensure trials lined up with the results that led to the accelerated provisional approval,” Gorksi said – a practice that Prasad sharply criticized, and a stance with which others including Gorski agreed.

But in 2021, he had a “heel turn” and began strenuously opposing Covid boosters and other precautions, like wearing face masks, as well, Gorski said. Prasad started questioning “how dangerous Covid actually was”, he said.

Prasad hasfrequentlyadvocatedfor removing the Covid vaccine from the US childhood immunization schedule, and that it was “malpractice” for doctors to recommend the booster for children.

Prasad said it was “only a matter of time” before a serious safety signal emerges from the vaccines, which have been administered to millions of people around the globe, and called annual update boosters “a game of Russian roulette” in ablogpost.

He believes the risk of myocarditis and other side effects from mRNA Covid shots outweigh the benefits of preventing illness and death. Myocarditis is a markedly more common side effect from Covid infection, which also remains a top cause of death.

“Dr Vinay Prasad spent the past four years spreading misinformation on Covid and the Covid vaccine,” said Jonathan Howard, an associate professor of neurology and psychiatry at NYU Langone Health and author of the book We Want Them Infected.

Prasad recently called for a clinical trial, separated by age, to assess the effectiveness of each updated Covid shot. The vaccine would only be authorized “if it works”, Prasadwrote– but he believed it won’t: “I suspect the trials may only be positive in the above 80 and nursing home group. The rest will be negative.”

Holding new trials for updated vaccines is unusual. It’s a lengthy process that means vaccines would likely not be available before the fall, when updated boosters have been rolled out in the past.

This approach would also throw flu vaccines into uncertainty. “It’s time to reform the flu vaccine process for the 21st century,” Prasadwrotein March.

Gorski doubts “that there will be an updated Covid vaccine” and doesn’t “think this will be an issue with the flu vaccines right away, but I think we’re moving that way”.

Covid (and flu) shots are still greatly needed, Gorski said, as “the virus keeps mutating and evolving to evade pre-existing immunity. It still kills a lot of people.”

Prasas has repeated several anti-vaccine talking points, including the call for more studies on the effects of clustering childhood immunizations together; a greater focus on saline placebo trials; and revamping the current system to allow more lawsuits against vaccine makers.

By criticizing how clinical trials are done, skeptics such as Prasad “cast doubt on the current evidence by implying that whatever you’re criticizing has never been adequately studied and probably doesn’t work”, Gorski said.

Prasad has alsoregularlymocked scientists and doctors for wearing masks, and hecalledthe public health workforce “the dumbest people in the country” and “dummies talking out their ass” because they are willing to accept low wages for their work.

He has repeatedly criticized Peter Marks, the person who last held this job and who says he was pushed out by health secretary Robert F Kennedy Jr, calling Marks “dangerous”. Prasad has also called out other officials previously at the helm of health agencies, including Mandy Cohen, Rochelle Walensky and Robert Califf.

“In my opinion, these pieces of shit are still lying,” Prasad said of public health leaders on a podcastinterview.

“Using vulgar, unprofessional language, Dr Prasad excoriated the previous medical establishment for not doing randomized-controlled trials for every variant and demographic. That’s his job now, and we can hold him to the same standards,” Howard said.

Gorski agreed: “He is now the medical-proof establishment. Prasad owns it now when it comes to vaccines – he owns it all.”

Back to Home
Source: The Guardian